Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know

Company Performance - Pfizer's stock closed at $24.70, reflecting a +0.65% change, which lagged behind the S&P 500's gain of 0.67% [1] - Over the past month, Pfizer's shares have decreased by 4.7%, compared to the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28% [1] Upcoming Earnings - Pfizer's earnings report is scheduled for April 29, 2025, with projected EPS of$ 0.68, indicating a 17.07% decline from the same quarter last year [2] - The consensus estimate for quarterly revenue is $13.99 billion, down 5.97% year-over-year [2] Full-Year Estimates - Full-year earnings estimates for Pfizer are$ 2.97 per share and revenue of $63.2 billion, representing year-over-year changes of -4.5% and -0.67%, respectively [3] - Recent revisions to analyst forecasts are crucial as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [3] Valuation Metrics - Pfizer has a Zacks Rank of 3 (Hold) and a Forward P/E ratio of 8.26, which is below the industry's average Forward P/E of 13.71 [5] - The PEG ratio for Pfizer is currently 0.6, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.31 [6] Industry Context - The Large Cap Pharmaceuticals industry is part of the Medical sector and holds a Zacks Industry Rank of 67, placing it in the top 27% of over 250 industries [6] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]